ABSTRACT
The hastily emerging antimicrobial resistance and the onset of deadly diseases have constantly built demand on hunting novel, unique, effective, sustainable exploitation of new antimicrobials for infinite therapeutics. However, these are the leading root of significant mortality all over the Globe. Despite this commitment, we are lusting to make novel therapeutic agents from biological sources. The natural compound has acted as an immune booster and a remedy for numerous ailments. It is sourced from plants, animals, and microbes. Connected to other origins, microbial-based natural products (NPs) occupy an appealing point for drug discovery. In particular, actinomycetes are known as well-documented biosynthetic factories and are contributing to producing an effectively extended spectrum of secondary entities with a wide range of biotechnological, pharmaceutical, and agricultural potentials. Actinomycetes are a copious supplier to find out a large number of lead compounds with multiple degrees of biological activities. Despite its historical multiplicity, remarkable novelty, prominent metabolism, genome versatility, and superior activity, actinomycetes have been continuing for the development of drug leads. Based on their silent secondary metabolite biosynthetic gene clusters (SM-BGC), they are not fully unrevealed. Of fresh, the stab of activation, whole-cell activation, and synthetic biology have evolved as a potent protocol to explore and enhance entire biosynthetic potentials of actinomycetes. In this chapter, we examine around to solidify an assortment of actinobacteria-derived natural commodities, principally antibacterials, antivirals, antifungals, and anti-cancer agents. In addition, it is a special endeavor to spotlight and activate the biosynthesis of secondary metabolites from actinomycetes using the whole-cell-biocatalysis and synthetic biology approach.
